Eton Pharmaceuticals Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Eton Pharmaceuticals Inc 's ROA in the third quarter of 2026?
Eton Pharmaceuticals Inc achieved a return on average assets (ROA) of 43.09 % in its third quarter of 2026, this is above ETON's average return on assets of -42.67%.
Eton Pharmaceuticals Inc assets over the 12 months ending in its third quarter of 2026 are valued at $116 million

ROA has improved compared to 12.37% in the second quarter of 2026, due to net income growth.

However, within the Healthcare sector 77 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 2715, from total ROA ranking in the second quarter of 2026 at 3458.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	50.49 %	13.9 %	16.28 %	21.01 %	191.59 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	50	13	-1	-5	-7
Return On Assets (TTM)	43.09 %	12.37 %	-1.49 %	-4.81 %	-7.3 %
ETON's Total Ranking	# 2715	# 3458	# 3184	# 3079	# 3257
Total Assets (TTM) in million	157	116	98	92	105
Seq. Total Assets Change	35.81 %	18.52 %	6.08 %	-11.86 %	2.79 %
Seq. Net Income Change	204.45 %	645.05 %	4.79 %	-	-

ETON's 5 Years Annual ROA >> Back to ETON Management Effectiveness >> Compare ETON ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 32
Sector	# 78
Overall	# 474

Return On Assets Statistics
High	Average	Low
12.37 %	-42.67 %	-160.95 %
(Jun 30 2026)		(Dec 31 2020)

News about Eton Pharmaceuticals Inc Return on Assets ROA

Eton Pharmaceuticals Expands Portfolio Through Acquisition of Increlex, Reinforcing Commitment to Rare Disease Patients

In a significant move that underscores its commitment to patients with ultra-rare conditions, Eton Pharmaceuticals, Inc. has announced the acquisition of Increlex (mecasermin injection) from Ipsen. This strategic decision not only broadens Eton s product offerings but also aligns with its mission to develop and distribute medicines that can dramatically change lives.Increlex is a crucial treatment for children with severe primary insulin-like growth factor-1 deficiency (IGFD), a rare disorder that can lead to severe growth impairment and other health complications. The drug functions by mimicking the action of natural IGF-1, thereby promoting growth in eligible patients who cannot produce sufficient quantities of this essential hormone. The acquisition of Increlex provides Eton with the opportunity to enhance its focus on rare diseases, where unmet needs are often most pronounced and treatment options can be limited.

Financial Statements
Eton Pharmaceuticals Inc 's Assets	$ 157 million	ETON's Balance sheet
Eton Pharmaceuticals Inc 's Income	$ 35 million	Quarterly ETON's Income Statement
ETON's Income by Division		See ETON's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	21.01 %	139.83 %	26.81 %	-8.87 %	4.35 %
Total Assets in million	92	76	32	25	27
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-5	-4	-1	-9	-2
Annual Return On Assets	-4.99 %	-5.02 %	-2.95 %	-36.04 %	-7.12 %

ETON's 5 Years Annual ROA >> Back to ETON Management Effectiveness >> Compare ETON ROA to its Competitors

More Return On Assets Ratios
ETON's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ETON's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ETON's Competitors
Subscribers only: Roa for Eton Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for ETON's Customers

You may also want to know
ETON's Roi	ETON's Inventory Turnover Ratio	ETON's Growth Rates	ETON's Dividend Comparisons
	ETON's Profitability Ratios	ETON's Asset Turnover Ratio	ETON's Dividend Growth
ETON's Roe	ETON's Valuation Ratios	ETON's Financial Strength Ratios	ETON's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector	ROA
Exelixis Inc	63.88 %
Rigel Pharmaceuticals Inc	59.56 %
Alnylam Pharmaceuticals Inc	46.08 %
Ironwood Pharmaceuticals inc	42.53 %
Aurinia Pharmaceuticals Inc	40.63 %
Nurix Therapeutics Inc	38.61 %
Indivior Pharmaceuticals Inc	36.35 %
Rallybio Corporation	34.55 %
Idexx Laboratories Inc	34.05 %
Zevra Therapeutics Inc	26.33 %
Caredx Inc	25.74 %
Medpace Holdings Inc	24.47 %
Acadia Pharmaceuticals Inc	21.60 %
Standard Biotools Inc	21.56 %
Eli Lilly And Company	21.24 %
Iradimed Corporation	20.89 %
Resmed Inc	18.67 %
Alector Inc	18.37 %
Corcept Therapeutics Inc	18.09 %
Chemed Corporation	17.73 %
Halozyme Therapeutics Inc	17.26 %
Pro dex Inc	16.75 %
Denali Therapeutics Inc	16.42 %
Krystal Biotech Inc	15.48 %
West Pharmaceutical Services Inc	15.47 %
Dexcom Inc	15.47 %
Intuitive Surgical Inc	14.71 %
Vertex Pharmaceuticals Inc	14.16 %
Neurocrine Biosciences Inc	13.69 %
Illumina Inc	13.43 %

Date modified: 2026-11-06T13:02:44+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.